A case report from NYU Langone Health assessed the use of both urgent and non-urgent telemedicine visits.
Officials with the FDA have issued an emergency use authorization for remdesivir (Gilead Sciences) for the treatment of suspected or laboratory-confirmed coronavirus disease 2019 (COVID-19) in hospitalized adults and children.
Officials with the FDA approved niraparib (Zejula, GlaxoSmithKline), a once-daily, oral monotherapy, for the first-line maintenance treatment of platinum-responsive advanced ovarian cancer regardless of biomarker status.
New clinical trial updates on remdesivir as a potential treatment for coronavirus disease 2019 (COVID-19) were announced today.
A recent study included interviews with pharmacists in rural Kentucky counties regarding pharmacy-level barriers to opioid use disorder treatment.
Six-year data from the new analyses add evidence to the benefit-risk profile of ocrelizumab (Ocrevus, Genentech) for patients with multiple sclerosis.
Regeneron and Sanofi will amend their ongoing trial of sarilumab (Kevzara) to enroll only “critical” hospitalized patients with COVID-19.
The FDA warned against the use of hydroxychloroquine and chloroquine outside of the hospital setting or clinical trials due to safety risks.
To date, 19 states have authorized pharmacists to order and conduct testing for COVID-19.
Two new studies underscore health disparities in rural United States affecting mortality rates associated with cardiovascular disease.